Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ADJUVANT CHEMOTHERAPY WITH DOXORUBICIN-CONTAINING REGIMEN FOR 326 STAGE-II BREAST CANCERS - 15-YEAR RESULTS
Autore:
FERRIERE JP; CHARRIER S; CURE H; KWIATKOWSKI F; COURTADON M; BELEMBAOGO E; DELATOUR M; ACHARD JL; DAUPLAT J; CHOLLET P;
Indirizzi:
CTR JEAN PERRIN,58 RUE MONTALEMBERT,BP 392 F-63011 CLERMONT FERRAN 1 FRANCE CTR JEAN PERRIN F-63011 CLERMONT FERRAN 1 FRANCE INSERM U 71 F-63011 CLERMONT FERRAN 1 FRANCE
Titolo Testata:
American journal of clinical oncology
fascicolo: 3, volume: 20, anno: 1997,
pagine: 219 - 225
SICI:
0277-3732(1997)20:3<219:ACWDRF>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Keywords:
ADJUVANT CHEMOTHERAPY; BREAST CANCER; DOXORUBICIN; CARDIAC EFFECTS; SURVIVAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
21
Recensione:
Indirizzi per estratti:
Citazione:
J.P. Ferriere et al., "ADJUVANT CHEMOTHERAPY WITH DOXORUBICIN-CONTAINING REGIMEN FOR 326 STAGE-II BREAST CANCERS - 15-YEAR RESULTS", American journal of clinical oncology, 20(3), 1997, pp. 219-225

Abstract

Between 1975 and 1986, 326 patients with stage II breast cancer were treated with an adjuvant combination of doxorubicin, vincristine, cyclophosphamide, and 5-fluorouracil (AVCF) following regional therapy (232 modified radical mastectomy, 94 lumpectomies, 304 irradiations). TheAVCF regimen consisted of 4-week cycles of doxorubicin (30 mg/m(2) day 1, modified radical mastectomy), vincristine (1 mg/m(2) day 2), 5-fluorouracil 400 (mg/m(2)), and cyclophosphamide (300 mg/m(2)) days 3-6. Two hundred twenty-four patients (pts) had six cycles and 102 pts 12 cycles; 90 pts also received 30 mg daily tamoxifen for 1 year after chemotherapy. As of March 1994, the median follow-up was 130 months (range 86-221). One hundred eighteen pts developed recurrences (7 local, 19 controlateral, 92 metastatic) and 104 died. Estimated disease-free survival (DFS) was 5 years, 76 +/- 5%; 10 years, 64 +/- 5%; 15 years, 54 +/- 9%. Overall survival (OS) was 5 years, 85 +/- 4%; 10 years, 70 +/- 5%; 15 years, 58 +/- 10%. Survival was affected by the number of involved lymph nodes (258 pts were N+), menopausal status (OS at 15 years: 53% for MP+ and 65% for MP-) and Scarff-Bloom-Richardson grading, but not by hormonal receptors, number of courses, or associated hormonotherapy. Minimal cardiac toxicity was induced by doxorubicin either during or subsequent to treatment completion.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 04:44:27